ACRV (ACRV) Stock Price & Analysis
ACRV (ACRV) fell 1.41% to USD 2.1 as of September 9, 2026 at 12:05 UTC, according to Nexqual real-time market data.
ACRV last closed at USD 2.13; the session ranged USD 2.07–2.18 on volume of 126,371 shares. Market capitalization is $89.99M, with a 52-week range of USD 1.27–3.56 (NGM). Source: Nexqual, September 9, 2026 at 12:05 UTC.
Key Statistics (as of September 9, 2026 at 12:05 UTC)
| Price | USD 2.1 |
|---|---|
| Change | ▼ 1.41% (down) |
| Previous Close | USD 2.13 |
| Open | USD 2.13 |
| Day Range | USD 2.07 – 2.18 |
| 52-Week Range | USD 1.27 – 3.56 |
| Volume | 126,371 shares |
| Market Cap | $89.99M |
| Exchange | NGM |
Technical Analysis (ACRV)
Nexqual's technical model rates ACRV "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 9, 2026 at 12:05 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.9 (neutral) |
| vs SMA50 | Above (USD 1.87) |
| MACD | 0.09 (positive) |
Analyst Ratings (ACRV)
Wall Street analysts rate ACRV "None" based on 6 analysts, with a mean price target of USD 11.5 (range USD 7–19), per Nexqual as of September 9, 2026 at 12:05 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 11.5 |
| High Target | USD 19 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (ACRV)
| EPS Estimate | USD -0.45 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.43 vs est -0.5 ▲ beat |
| 2026-03-31 | USD -0.49 vs est -0.52 ▲ beat |
| 2025-12-31 | USD -0.49 vs est -0.46 ▼ miss |
| 2025-09-30 | USD -0.47 vs est -0.58 ▲ beat |
Source: Nexqual, September 9, 2026 at 12:05 UTC.
Financials & Fundamentals (ACRV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -64.63% |
| Debt / Equity | 2.44 |
| Current Ratio | 7.99 |
| Total Cash | $89.96M |
| Total Debt | $2.12M |
| Free Cash Flow | $-39.82M |
Source: Nexqual, September 9, 2026 at 12:05 UTC.
Financial Health Score (ACRV)
Nexqual rates ACRV's overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 12:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $90M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$63M |
| Efficiency | Critical — ROE -65%, ROA -38.0% |
Ownership (ACRV)
| Insider Ownership | +15.40% |
|---|---|
| Institutional Ownership | +50.34% |
| Shares Outstanding | 42.85M |
| Float | 25.66M |
| Short % of Float | +4.30% |
Source: Nexqual, September 9, 2026 at 12:05 UTC.
Leadership (ACRV)
ACRV is led by Peter Blume-Jensen (age 62), Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer, per Nexqual as of September 9, 2026 at 12:05 UTC.
| Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer | Peter Blume-Jensen (age 62) |
|---|---|
| Co-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director | Kristina Masson (age 45) |
| Chief Operating Officer | Eric J. Devroe (age 46) |
| CFO & Principal Financial Officer | Adam D. Levy (age 59) |
| Vice President of Finance & Accounting | Katharine Peterson |
Major Backers & Investors (ACRV)
Notable institutional backers of ACRV include RA Capital Management, L.P., Sands Capital Alternatives, LLC, Acadian Asset Management. LLC, according to Nexqual as of September 9, 2026 at 12:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 28.54% |
| Sands Capital Alternatives, LLC | 5.34% |
| Acadian Asset Management. LLC | 2.72% |
| Wellington Management | 2.07% |
| Renaissance Technologies | 1.77% |
| Two Sigma Investments, LP | 1.5% |
| Marshall Wace LLP | 1.24% |
| Bridgeway Capital Management, LLC | 0.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.44% |
Source: Nexqual, September 9, 2026 at 12:05 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PEPG | PepGen Inc. | USD 3.21 | ▲ 0.94% |
| RLYB | Rallybio Corporation | USD 16.61 | ▼ 1.57% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 14.27 | ▼ 0.76% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 3.16 | ▲ 2.27% |
| TCRX | TScan Therapeutics, Inc. | USD 0.34 | ▼ 7.06% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 12:05 UTC. This page is informational and not investment advice.